TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04274348

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsies and blood samples
Description: Two skin biopsies and 30 ml of blood will be collected.
Study: NCT04068857

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
Study: NCT05246540

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT01400932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI148512
Description: GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
Study: NCT02933918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Safety of nasal irrigation with probiotics in healthy volunteers
Study: NCT03105739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LMA removal
Description: According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LMA removal
Description: According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
Study: NCT01860560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Therapy
Description: Blower-based High Flow Therapy delivered by nasal cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Therapy
Description: Blower-based High Flow Therapy delivered by nasal cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
Study: NCT01846455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0mg Buprenorphine/0.5mg Naloxone
Description: Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0mg Buprenorphine/0.5mg Naloxone
Description: Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0mg Buprenorphine/0.5mg Naloxone
Description: Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0mg Buprenorphine/0.5mg Naloxone
Description: Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.0mg Buprenorphine/0.5mg Naloxone
Description: Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promethazine
Description: Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
Study: NCT04261530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music/self-care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-care
Study: NCT00724542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose tablets
Description: 0.2mg Tid
Study: NCT04261530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education
Study: NCT02427282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: miniscrew-supported Frog molar distalizing appliance
Description: miniscrew 10mm length and 1.7mm diameter FORESTADENT company

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Frog molar distalizing appliance
Description: Nance buttons attached to first premolars band
Study: NCT04507009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone
Description: topical gaseous ozone application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone
Description: topical gaseous ozone application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGF
Description: concentrated growth factor (CGF) application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: Alvogyl application
Study: NCT04092842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone prosthesis
Description: Silicone prosthesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice
Description: Usual surgery
Study: NCT00595231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN111
Description: 500 mg for 1 week followed by 1000 mg for 7 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg tablets
Study: NCT01993888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVARREST® Fibrin Sealant Patch

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Study: NCT05317767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M [Inactivated split influenza vaccine]
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Split Influenza Vaccine
Description: solution for intramuscular injection, 0.5 ml
Study: NCT04222283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIKTARVY 50Mg-200Mg-25Mg Tablet
Description: At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).
Study: NCT00806221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emollient (Cetaphil cream)
Description: Cetaphil cream applied daily from birth
Study: NCT00999830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2101
Description: One infusion of IPH2101 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2101
Description: One infusion of IPH2101 every 4 weeks
Study: NCT00003200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study: NCT04321811

Intervention type: OTHER
Intervention: Observation of patients with known, suspected, or at risk for COVID-19 infection
Description: Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.
Study: NCT01200433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
Study: NCT00832819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080
Description: Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080
Description: Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
Study: NCT03250286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS
Description: Endoscopic ultrasound (EUS) is performed with radial scanning echo endoscope (Olympus GF UE260) by four endosonographers.~EUS examination is performed first, and if there is choledocholith, ERCP is performed.
Study: NCT00832819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
Study: NCT03993717

Intervention type: BIOLOGICAL
Intervention: SHINGRIX
Description: A single intramuscular injection of the FDA-approved recombinant glycoprotein E herpes zoster (HZ/su) vaccine will be administered in the deltoid muscle of the preferred arm

Intervention type: BIOLOGICAL
Intervention: SHINGRIX
Description: A single intramuscular injection of the FDA-approved recombinant glycoprotein E herpes zoster (HZ/su) vaccine will be administered in the deltoid muscle of the preferred arm
Study: NCT03250286

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.~* In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.~* In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.~* In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.~* In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP.
Study: NCT03579095

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cereboost
Description: 200mg Cereboost and Maltodextrin capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg Maltodextrin capsules
Study: NCT01826409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Red Ginseng
Description: Fermented red ginseng 2.7g/day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.7g/day for 4 weeks
Study: NCT01415557

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Fortified Control Product
Description: Non-Fortified Control Beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient Fortified Test Product
Description: Micronutrient Fortified Test Beverage
Study: NCT00737490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sequential Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)
Description: Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm~Using one of the FDA approved St. Jude devices, depending on MD preference.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)
Description: simultaneous BiV pacing.~Using one of the FDA approved St. Jude devices, depending on MD preference.
Study: NCT03393728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Description: 72-hour propanolol before specific treatment of hyperthyroidism
Study: NCT02459951

Intervention type: OTHER
Intervention: clenched fist
Description: Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
Study: NCT00667095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Instillation
Description: Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSO Instillation
Description: DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMSO Instillation
Description: DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
Study: NCT02608788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S.L.®
Description: 1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difflam Forte ®
Description: 3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Study: NCT02566005

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley bulb
Description: a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
Study: NCT01231165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: 5mg/daily for 12th months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrates, clopidogrel, aspirin, statins
Description: Comparative Efficacious Research
Study: NCT02562625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Powder solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Powder solution for infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 24Gy
Study: NCT03276741

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gastric soft/bland diet
Description: Patients in the experimental group will have a gastric soft/bland diet available.
Study: NCT00317044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 40 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 40 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study: NCT04647110

Intervention type: DRUG
Intervention: crizotinib
Description: as provided in real world practice

Intervention type: DRUG
Intervention: alectinib
Description: as provided in real world practice

Intervention type: DRUG
Intervention: brigatinib
Description: as provided in real world practice

Intervention type: DRUG
Intervention: ceritinib
Description: as provided in real world practice

Intervention type: DRUG
Intervention: lorlatinib
Description: as provided in real world practice
Study: NCT01067820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo RVX000222
Description: capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
Study: NCT00975091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
Study: NCT00755820

Intervention type: BEHAVIORAL
Intervention: Exposure Therapy + D-Cycloserine
Description: Exposure therapy with d-cycloserine medication

Intervention type: BEHAVIORAL
Intervention: Exposure Therapy + Placebo
Description: Exposure therapy with placebo medication

Intervention type: BEHAVIORAL
Intervention: Supportive Psychotherapy
Description: Supportive psychotherapy
Study: NCT02285400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP level
Description: CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP level
Description: CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
Study: NCT02104063

Intervention type: PROCEDURE
Intervention: MRI-PET
Description: Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
Study: NCT04807361

Intervention type: BEHAVIORAL
Intervention: Auditory biofeedback traing
Description: Subjects who wear MFCLs for myopia control will receive one episode of auditory biofeedback training, and their accommodative responses to various demands (0, 2.5, 3, and 4 D) before and after the training were measured using a power refractor.
Study: NCT00318292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine and epinephrine
Description: 20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml normal saline injection.